Barrington Research Reaffirms Outperform Rating for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE)‘s stock had its “outperform” rating restated by equities research analysts at Barrington Research in a report issued on Monday,Benzinga reports. They currently have a $93.00 price objective on the medical instruments supplier’s stock. Barrington Research’s target price would indicate a potential upside of 39.76% from the stock’s current price.

Several other analysts have also recently commented on HAE. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. Citigroup reduced their price objective on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. BTIG Research reaffirmed a “buy” rating and set a $88.00 price target on shares of Haemonetics in a research note on Friday, January 9th. Finally, Mizuho lifted their price target on Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Stock Up 0.9%

NYSE HAE opened at $66.54 on Monday. The company has a market capitalization of $3.11 billion, a P/E ratio of 19.46, a PEG ratio of 1.38 and a beta of 0.28. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The company’s 50 day simple moving average is $78.47 and its 200 day simple moving average is $65.38. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts expect that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently bought and sold shares of HAE. True Wealth Design LLC increased its holdings in shares of Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 335 shares during the period. EverSource Wealth Advisors LLC increased its stake in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the period. GAMMA Investing LLC grew its holdings in shares of Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 165 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 567 shares during the period. Finally, Bayforest Capital Ltd acquired a new position in shares of Haemonetics in the fourth quarter valued at $40,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.